中德临床肿瘤学杂志（英文版）2009，Vol.8Issue(7)：411-414,4.
卡培他滨联合奥沙利铂治疗进展期胃癌68例
Clinical observation of capecitabine plus oxaliplatin in treatment of 68 cases with advanced gastric cancer
Chaoying Liu 1Jiang Li 1Runjie Wang 1Hong Hu 1Juanying Xu1
作者信息
- 1. Department of Medical Oncology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China
- 折叠
摘要
Abstract
Objective: The aim of this study was to evaluate the response rate, time to progression (TTP), overall survival, and safety of the combination of capecitabine plus oxaliplatin in treatment of advanced gastric cancer (AGC). Methods: All the patients with advanced gastric cancer who were not received any prior chemotherapy or radiotherapy were treated with combination of capecitabine (1250 mg/m2 twice daily, days 1-14) plus oxaliplatin (130 mg/m2 as a 2-h intravenous infusion on day 1) every 3 weeks. Results: Two cases of complete response (CR) and 34 cases of partial response (PR) were confirmed, giving an overall response rate of 52.9%, of the 68 patients with advanced gastric cancer. The median TTP and overall survival for all patients were 7.3 and 11.9 months, respectively. Grade 3 leukopenia, thrembocytopenia, nausealvomiting, and diarrhea were observed in 3, 5, 1, and 4 patients, respectively. Yet, no grade 4 toxicity was observed. Conclusion: Capecitabine/ oxaliplatin combination chemotherapy is active in patients with advanced gastric cancer.关键词
advanced gastric cancer (AGC)/chemotherapy/capecitabine/oxaliplatinKey words
advanced gastric cancer (AGC)/chemotherapy/capecitabine/oxaliplatin分类
医药卫生引用本文复制引用
Chaoying Liu,Jiang Li,Runjie Wang,Hong Hu,Juanying Xu..卡培他滨联合奥沙利铂治疗进展期胃癌68例[J].中德临床肿瘤学杂志（英文版）,2009,8(7):411-414,4.
